Received May 28, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 2 | UNK | — |
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | UNK | — |
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 2 | UNK | — |
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | UNK | — |
One month later the virus went to my braIn and I developed encephalitis which put me in the hospital for 3 days; developed lesions; This serious case was reported by a consumer via interactive digital media and described the occurrence of encephalitis in a 87-year-old patient who received Herpes zoster (Shingles vaccine) solution for injection for prophylaxis. On an unknown date, the patient received the 2nd dose of Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced encephalitis (Verbatim: One month later the virus went to my braIn and I developed encephalitis which put me in the hospital for 3 days) (serious criteria hospitalization and GSK medically significant) and skin lesion (Verbatim: developed lesions). The outcome of the encephalitis was not reported and the outcome of the skin lesion was not resolved. It was unknown if the reporter considered the encephalitis and skin lesion to be related to Shingles vaccine. The company considered the encephalitis to be unrelated to Shingles vaccine. Additional Information: GSK Receipt Date: 25-MAY-2026 This case was reported by a consumer via interactive digital media. The shingles vaccine was not full proof. The patient had both shots and, at age 87, developed lesions. The lasting effects on the patient's central nervous system were disastrous. The patient stated that every shingles patient over 60 needs to see a doctor who knows what they were doing. The batch number was not provided, and unable to contact the reporter.; Sender's Comments: A case of Encephalitis, unknown time receiving 2nd dose of Shingles vaccine, in a 87-year-old patient. Based on the available information a possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow-up has not been received.